RE: Medicines vs Vaccines in the fight against COVID08 May 2021 20:16
Tommy, If you view this from the point of view of the whole world rather than just the UK then it is clear there is a huge need for treatments alongside vaccines. If you look at influenza in the US alone, there is on an annual basis 300-750k hospitalisation per year. This was before covid and there has been a flu vaccine for years. I know the board has been over this a lot since last November when vaccine news hit when even the likes of Prof John Bell claimed it would be all over by Easter yet here we are with more infections per day worldwide than we had back in the depths of winter.
RE: New Synairgen CCO (hired in Dec 2020)08 May 2021 17:41
Funny how the green boxes have all dried up with this news. Great to have this board back to some excellent discussion for a change. This small company has been working its arse off for the last 16 months trying to find an extra weapon to fight this horrible virus and it's great to see that they have the quality of Mr Hennings in a position to help get this drug to market asap.
RE: Magnificent 7.... tells us something...06 May 2021 22:02
Spade, Sorry my badI thought it got back to low 30's. I agree with you when it got to high 20's I didn't envisage a drop to the teens and so held like most others I expect. It is what it is. An opportunity to add more.
RE: Magnificent 7.... tells us something...06 May 2021 20:19
Good post Strummer. I don't think there were too many that managed to sell at the top. In any case when invested in an explorer and there are results pending on a highly prospective target like Scally I am not sure many would have risked selling at that point. There were still opportunities to sell in the low 30's high 20's after Scally news. That is where the more sophisticated investors may have won. Alas I am not one of those and have held all they way since March 2020 without selling. For me I am happy to hold for the long term and then add when opportunities like 18/19/20p come around like this and accumulate as many shares as possible.
Snowwoman, With regard to commercialisation RM said in November they had consultants working on this as well as manufacturing. Since then they have recruited a number of positions to deal with manufacturing and as the company draws closer to commercialisation then I am sure recruitment in this area will ramp up. IMO no point in wasting money on commercial staff until you have product to sell. Their non exec's have serious pharma commercial experience and at this stage of the companies development that is sufficient IMO.
"@JimBethell We’re investing in 2m LFDs per week by end May from British firms @OmegaDiagnostic and @mologic to stop the spread of COVID-19. Investment in talent will help "build back better" & create 100s of jobs".
Sovereign test just waiting for CE mark by Mologic!
This is interesting. Nasal tissues exhibit strong INF response whereas lung tissues don’t.“ Importantly, SARS-CoV-2 infection triggered robust antiviral and inflammatory innate immune responses in the nasal mucosa. The upregulationof interferon stimulated genes, cytokines and chemokines, related to interferon signaling and immune-cell activation pathways, was broader than that triggered by influenza virus infection. Conversely, lung tissues exhibited a restricted innate immune response to SARS-CoV-2, with a conspicuous lack of type I and III interferon upregulation, contrasting with their vigorous innate immune response to influenza virus. Our findings reveal differential tissue-specific innate immuneresponses in the upper and lower respiratory tract, that are distinct to SARS-CoV-2. The studies shed light on the role of the nasal-mucosa in active viral transmission and immune defense, implying a window of opportunity for early interventions,whereas the restricted innate immune response in early-SARS-CoV-2-infected lung tissues could underlie the unique uncontrolled late-phase lung damage of advanced COVID-19.”https://jvi.asm.org/content/jvi/early/2021/04/22/JVI.00130-21.full.pdf